Fargnoli Maria Concetta, Pike Kris, Pfeiffer Ruth M, Tsang Shirley, Rozenblum Ester, Munroe David J, Golubeva Yelena, Calista Donato, Seidenari Stefania, Massi Daniela, Carli Paolo, Bauer Juergen, Elder David E, Bastian Boris C, Peris Ketty, Landi Maria T
Department of Dermatology, University of L'Aquila, L'Aquila, Italy.
J Invest Dermatol. 2008 Oct;128(10):2485-90. doi: 10.1038/jid.2008.67. Epub 2008 Mar 27.
Melanocortin-1 receptor (MC1R) variants have been associated with BRAF (v-raf murine sarcoma viral oncogene homolog B1) mutations in non-CSD (chronic solar-damaged) melanomas in an Italian and an American population. We studied an independent Italian population of 330 subjects (165 melanoma patients and 165 controls) to verify and estimate the magnitude of this association and to explore possible effect modifiers. We sequenced MC1R in all subjects and exon 15 of BRAF in 92/165 melanoma patients. Patients with MC1R variants had a high risk of carrying BRAF mutations in melanomas (odds ratio (OR)=7.0, 95% confidence interval (CI)=2.1-23.8) that increased with the number of MC1R variants and variants associated with red hair color. Combining these subjects with the originally reported Italian population (513 subjects overall), MC1R variant carriers had a 5- to 15-fold increased risk of BRAF-mutant melanomas based on carrying one or two variants (P<0.0001, test for trend), and regardless of signs of chronic solar damage. In contrast, no association with BRAF-negative melanomas was found (OR=1.0, 95% CI=0.6-1.6). No characteristics of subjects or melanomas, including age, nevus count, pigmentation, and melanoma thickness or location on chronically or intermittently sun-exposed body sites, substantially modified this association, although results could be affected by the small numbers in some categories. This study confirms that the known MC1R-melanoma risk association is confined to subjects whose melanomas harbor BRAF mutations.
在意大利和美国人群中,黑皮质素-1受体(MC1R)变体已与非慢性日光损伤(CSD)黑色素瘤中的BRAF(v-raf鼠肉瘤病毒癌基因同源物B1)突变相关。我们研究了一个由330名受试者组成的独立意大利人群(165例黑色素瘤患者和165名对照),以验证和估计这种关联的强度,并探索可能的效应修饰因素。我们对所有受试者的MC1R进行了测序,并对92/165例黑色素瘤患者的BRAF第15外显子进行了测序。携带MC1R变体的患者在黑色素瘤中携带BRAF突变的风险较高(优势比(OR)=7.0,95%置信区间(CI)=2.1-23.8),且随着MC1R变体数量以及与红发颜色相关变体数量的增加而升高。将这些受试者与最初报道的意大利人群(共513名受试者)相结合,基于携带一个或两个变体,MC1R变体携带者患BRAF突变型黑色素瘤的风险增加了5至15倍(P<0.0001,趋势检验),且与慢性日光损伤的体征无关。相比之下,未发现与BRAF阴性黑色素瘤存在关联(OR=1.0,95%CI=0.6-1.6)。尽管某些类别中的样本量较小可能会影响结果,但受试者或黑色素瘤的特征,包括年龄、痣数量、色素沉着以及黑色素瘤厚度或在长期或间歇性暴露于阳光的身体部位的位置,均未对这种关联产生实质性影响。这项研究证实,已知的MC1R-黑色素瘤风险关联仅限于其黑色素瘤携带BRAF突变的受试者。